TSC22D3 and colitis: While TSC22D3 is commonly regarded as an anti-inflammatory therapeutic protein, reduced TSC22D3 expression has been reported to increase the release of pro-inflammatory factors and thus contribute to the development of inflammatory conditions such as colitis or liver fibrosis [33, 73].